Recently, the U.S. Food and Drug Administration (FDA) approved the
use of Gleevec in combination with chemotherapy to treat newly
diagnosed children with Philadelphia chromosome-positive acute
lymphocytic leukemia (Ph+ ALL).
While this is good news, it comes more than 10 years after it was
approved in adults and about 8 years after I treated my first
pediatric patient with chemotherapy plus Gleevec followed by a stem